W. Zheng

Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer

Fan Zhou, Xin Yu, Linquan Wu, 2016, Cancer biology & therapy.

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

H. Zhang, Yi-long Wu, B. Han, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity

L. Ouyang, L. Fang, Yi-nuo Zhang, 2022, Frontiers in Immunology.

Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.

Ying Cheng, Y. Shu, M. Dvorkin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis

K. Yang, S. Lu, Y. Song, 2022, Immuno-Oncology and Technology.

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Y. Shu, M. Dvorkin, Jie-Xie Wang, 2022 .

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.

Dingzhi Huang, S. Leaw, Xingya Li, 2024, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.